Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms Double-ITK-GVHc
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 07 Jul 2018 This trial has been completed in France, according to European Clinical Trials Database.
- 19 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.